Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01236443 · ClinicalTrials.gov registry record · Phase 1
Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01236443 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT01236443, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
A Study to identify toxicity and optimal photodynamic treatment parameters using the photosensitizer 2-\[1-hydroxyethyl\]-2-devinylpyropheophorbide-a (HPPH) in high grade dysplasia, carcinoma-in-situ, or early adenocarcinoma in Barrett's esophagus.
Interventions
- DRUG HPPH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2000-08 |
| Est. Completion | 2013-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01236443
The ClinicalTrials.gov registry entry for NCT01236443 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HPPH is the first listed.
NCT01236443 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01236443 about?
NCT01236443 is a clinical study titled "Study of Photodynamic Therapy (PDT) Using HPPH in Barrett's Esophagus". A Study to identify toxicity and optimal photodynamic treatment parameters using the photosensitizer 2-\[1-hydroxyethyl\]-2-devinylpyropheophorbide-a (HPPH) in high grade dysplasia, carcinoma-in-situ, or early adenocarcinoma in Barrett's esophagus.
What is the current status of trial NCT01236443?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2000-08. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01236443?
The interventions under investigation include: HPPH (DRUG).
Who is sponsoring clinical trial NCT01236443?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.